Inovio Pharmaceuticals, Inc.
0 products tracked · names used in filings: Inovio Pharmaceuticals, Inc.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
INO-3107: PDUFA target action date (Recurrent Respiratory Papillomatosis (RRP))
Inovio Pharmaceuticals, Inc. (INO); BLA; status: set; "Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 • Commercial preparations advancing in anticipation of potential product…"; filed 2026-08-12 · source
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.